Objective
To prove the superior performance of the Ranger™ paclitaxel-coated PTA balloon catheter (Boston Scientific) for angioplasty for femoropopliteal artery lesions when compared to non-coated balloons.

Trial Design
Prospective, multicenter, randomized, controlled trial (2:1 Ranger DCB vs. non-drug-coated balloon). Follow up through 3 years.

Key Enrollment Criteria
- Rutherford 2, 3 or 4
- Stenotic, restenotic or occlusive lesions (≥70% stenosis) in the native non-stented SFA/PPA
- No prior treatment with drug coated balloons or drug-eluting stents in the treated limb
- Lesion length ≥20 mm and ≤150 mm

Key Baseline Lesion Characteristics

<table>
<thead>
<tr>
<th></th>
<th>PTA (34)</th>
<th>Ranger DCB (71)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target Lesion Length (mm)</td>
<td>60 ± 48</td>
<td>68 ± 46</td>
</tr>
<tr>
<td>Reference Vessel Diameter (mm)</td>
<td>4.5 ± 0.83</td>
<td>5 ± 0.89</td>
</tr>
<tr>
<td>Percent Diameter Stenosis (%)</td>
<td>82 ± 18</td>
<td>85 ± 15</td>
</tr>
<tr>
<td>Total Occlusions (%)</td>
<td>34</td>
<td>34</td>
</tr>
</tbody>
</table>

12 Month Outcome

Patency
- Ranger achieved an 86% primary patency at 12 months (patent by DUS and without reintervention)
- Ranger demonstrated primary patency superior* to PTA

Freedom from TLR
- Ranger achieved a 91% Freedom from TLR at 12 months
- Ranger demonstrated Freedom from TLR superior* to PTA

* p<0.001 log rank test, Kaplan-Meier Analysis

Presented by Prof. Scheinert, Charing Cross - 2017
RANGER™ SFA Trial
12-month results presented at Charing Cross 2017

Patient Outcomes

Rutherford score
- 84% of Ranger subjects had no or mild symptoms - Rutherford category 0 or 1
- Compared to baseline, Ranger and PTA groups both showed improvement in Rutherford score and ABI

Conclusions
- Greater patency rate at 12 months for Ranger DCB than Control (86% vs 56%)
- Freedom from TLR greater for Ranger DCB than Control at 12 months (91% vs 70%)
- Patients treated with Ranger DCB demonstrated significant improvements in symptoms and hemodynamics at 12 months
  - Symptomatic improvement generally similar to Control but with ~1/3 as many revascularizations

Primary Patency at 12 months from DCB trials of the SFA

TLR at 12 months from DCB trials of the SFA

ILEMENATE  
RANGER  
IN.PACT  
LEVANT 2  
LEVANT 1

ILEMENATE  
RANGER  
IN.PACT  
LEVANT 2  
LEVANT 1

References: